tiprankstipranks
Trending News
More News >
Glaukos (GKOS)
NYSE:GKOS
US Market
Advertisement

Glaukos (GKOS) Stock Forecast & Price Target

Compare
349 Followers
See the Price Targets and Ratings of:

GKOS Analyst Ratings

Strong Buy
13Ratings
Strong Buy
11 Buy
2 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Glaukos
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GKOS Stock 12 Month Forecast

Average Price Target

$124.75
▲(31.15% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $124.75 with a high forecast of $165.00 and a low forecast of $92.00. The average price target represents a 31.15% change from the last price of $95.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","103":"$103","124":"$124","145":"$145","166":"$166"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$124.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,103,124,145,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.16,92.22461538461538,98.28923076923077,104.35384615384615,110.41846153846154,116.48307692307692,122.5476923076923,128.6123076923077,134.67692307692306,140.74153846153845,146.80615384615385,152.8707692307692,158.9353846153846,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.16,89.12846153846154,92.09692307692308,95.06538461538462,98.03384615384616,101.0023076923077,103.97076923076924,106.93923076923076,109.90769230769232,112.87615384615384,115.8446153846154,118.81307692307692,121.78153846153846,{"y":124.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.16,86.60923076923076,87.05846153846153,87.50769230769231,87.95692307692308,88.40615384615384,88.85538461538461,89.30461538461539,89.75384615384615,90.20307692307692,90.65230769230769,91.10153846153847,91.55076923076923,{"y":92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":117.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.44,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.54,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$165.00Average Price Target$124.75Lowest Price Target$92.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GKOS
William Blair
William Blair
Buy
Reiterated
08/27/25
William Blair Keeps Their Buy Rating on Glaukos (GKOS)
TR | OpenAI - 4o Analyst forecast on GKOS
TR | OpenAI - 4o
TR | OpenAI - 4o
$87$92
Hold
-3.28%
Downside
Reiterated
08/26/25
AI Generated ArticleAI Generated Article
Wells Fargo Analyst forecast on GKOS
Wells Fargo
Wells Fargo
$92
Hold
-3.28%
Downside
Reiterated
08/12/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Glaukos (NYSE: GKOS)
Piper Sandler Analyst forecast on GKOS
Piper Sandler
Piper Sandler
$165
Buy
73.47%
Upside
Reiterated
08/07/25
Piper Sandler Sticks to Their Buy Rating for Glaukos (GKOS)
Truist Financial Analyst forecast on GKOS
Truist Financial
Truist Financial
$130$126
Buy
32.46%
Upside
Reiterated
07/31/25
Truist Financial Remains a Buy on Glaukos (GKOS)
Mizuho Securities Analyst forecast on GKOS
Mizuho Securities
Mizuho Securities
$150$130
Buy
36.67%
Upside
Reiterated
07/31/25
Glaukos price target lowered to $130 from $150 at MizuhoGlaukos price target lowered to $130 from $150 at Mizuho
UBS
$125$134
Buy
40.87%
Upside
Reiterated
07/31/25
Glaukos Corporation (GKOS) PT Raised to $134 at UBSUBS analyst Danielle Antalffy raised the price target on Glaukos Corporation (NYSE: GKOS) to $134.00 (from $125.00) while maintaining a Buy rating.
J.P. Morgan Analyst forecast on GKOS
J.P. Morgan
J.P. Morgan
$100$110
Buy
15.64%
Upside
Reiterated
07/31/25
J.P. Morgan Sticks to Their Buy Rating for Glaukos (GKOS)JPMorgan analyst Allen Gong raised the price target on Glaukos Corporation (NYSE: GKOS) to $110.00 (from $100.00) while maintaining a Overweight rating.
Needham
$115
Buy
20.90%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Glaukos (NYSE: GKOS)
Stifel Nicolaus Analyst forecast on GKOS
Stifel Nicolaus
Stifel Nicolaus
$115
Buy
20.90%
Upside
Reiterated
07/31/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: GE Healthcare Technologies Inc (NASDAQ: GEHC), Humana (NYSE: HUM) and Glaukos (NYSE: GKOS)
BTIG
$117$118
Buy
24.05%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL) and Glaukos (NYSE: GKOS)We maintain our Buy and adjust our PT to $118 (from $117) following 2Q25 results. GKOS reported 2Q25 rev. of $124.1M (29.7% Y/Y , 28.6% Y/Y xFx), relative to BTIG/Cons. ests. of $117.4M/$115.5M. Glaucoma rev. of $103.5M (36.4% Y/Y) was favorable to our est. of $97.2M as iDose contributed ~$31.0M coupled with a decline of 9.0% in the US legacy surgical glaucoma portfolio. Guidance for FY25 was raised modestly to $480M-$486M (from $475M - $485M previously) as the mix shifts toward iDose offset by slightly lower US Glaucoma sales and slight changes to OUS Glaucoma and Corneal Health. All told, we think the iDose results exceeded the Buyside expectations of $28M - $30M in the quarter which keeps investors supportive of the potential in iDose. Mgmt. commentary on growing MAC coverage and adoption should be viewed favorably by longs.
Citi
$140
Buy
47.18%
Upside
Reiterated
07/07/25
Citi Keeps Their Buy Rating on Glaukos (GKOS)
Jefferies
$160
Buy
68.21%
Upside
Assigned
06/04/25
Promising Outlook for Glaukos: Strategic Advancements and Market Growth Drive Buy Rating
Stephens
$140$115
Buy
20.90%
Upside
Reiterated
05/02/25
Glaukos price target lowered to $115 from $140 at StephensGlaukos price target lowered to $115 from $140 at Stephens
Morgan Stanley Analyst forecast on GKOS
Morgan Stanley
Morgan Stanley
$120$110
Sell
15.64%
Upside
Reiterated
02/26/25
Morgan Stanley Reaffirms Their Sell Rating on Glaukos (GKOS)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GKOS
William Blair
William Blair
Buy
Reiterated
08/27/25
William Blair Keeps Their Buy Rating on Glaukos (GKOS)
TR | OpenAI - 4o Analyst forecast on GKOS
TR | OpenAI - 4o
TR | OpenAI - 4o
$87$92
Hold
-3.28%
Downside
Reiterated
08/26/25
AI Generated ArticleAI Generated Article
Wells Fargo Analyst forecast on GKOS
Wells Fargo
Wells Fargo
$92
Hold
-3.28%
Downside
Reiterated
08/12/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Glaukos (NYSE: GKOS)
Piper Sandler Analyst forecast on GKOS
Piper Sandler
Piper Sandler
$165
Buy
73.47%
Upside
Reiterated
08/07/25
Piper Sandler Sticks to Their Buy Rating for Glaukos (GKOS)
Truist Financial Analyst forecast on GKOS
Truist Financial
Truist Financial
$130$126
Buy
32.46%
Upside
Reiterated
07/31/25
Truist Financial Remains a Buy on Glaukos (GKOS)
Mizuho Securities Analyst forecast on GKOS
Mizuho Securities
Mizuho Securities
$150$130
Buy
36.67%
Upside
Reiterated
07/31/25
Glaukos price target lowered to $130 from $150 at MizuhoGlaukos price target lowered to $130 from $150 at Mizuho
UBS
$125$134
Buy
40.87%
Upside
Reiterated
07/31/25
Glaukos Corporation (GKOS) PT Raised to $134 at UBSUBS analyst Danielle Antalffy raised the price target on Glaukos Corporation (NYSE: GKOS) to $134.00 (from $125.00) while maintaining a Buy rating.
J.P. Morgan Analyst forecast on GKOS
J.P. Morgan
J.P. Morgan
$100$110
Buy
15.64%
Upside
Reiterated
07/31/25
J.P. Morgan Sticks to Their Buy Rating for Glaukos (GKOS)JPMorgan analyst Allen Gong raised the price target on Glaukos Corporation (NYSE: GKOS) to $110.00 (from $100.00) while maintaining a Overweight rating.
Needham
$115
Buy
20.90%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Glaukos (NYSE: GKOS)
Stifel Nicolaus Analyst forecast on GKOS
Stifel Nicolaus
Stifel Nicolaus
$115
Buy
20.90%
Upside
Reiterated
07/31/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: GE Healthcare Technologies Inc (NASDAQ: GEHC), Humana (NYSE: HUM) and Glaukos (NYSE: GKOS)
BTIG
$117$118
Buy
24.05%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL) and Glaukos (NYSE: GKOS)We maintain our Buy and adjust our PT to $118 (from $117) following 2Q25 results. GKOS reported 2Q25 rev. of $124.1M (29.7% Y/Y , 28.6% Y/Y xFx), relative to BTIG/Cons. ests. of $117.4M/$115.5M. Glaucoma rev. of $103.5M (36.4% Y/Y) was favorable to our est. of $97.2M as iDose contributed ~$31.0M coupled with a decline of 9.0% in the US legacy surgical glaucoma portfolio. Guidance for FY25 was raised modestly to $480M-$486M (from $475M - $485M previously) as the mix shifts toward iDose offset by slightly lower US Glaucoma sales and slight changes to OUS Glaucoma and Corneal Health. All told, we think the iDose results exceeded the Buyside expectations of $28M - $30M in the quarter which keeps investors supportive of the potential in iDose. Mgmt. commentary on growing MAC coverage and adoption should be viewed favorably by longs.
Citi
$140
Buy
47.18%
Upside
Reiterated
07/07/25
Citi Keeps Their Buy Rating on Glaukos (GKOS)
Jefferies
$160
Buy
68.21%
Upside
Assigned
06/04/25
Promising Outlook for Glaukos: Strategic Advancements and Market Growth Drive Buy Rating
Stephens
$140$115
Buy
20.90%
Upside
Reiterated
05/02/25
Glaukos price target lowered to $115 from $140 at StephensGlaukos price target lowered to $115 from $140 at Stephens
Morgan Stanley Analyst forecast on GKOS
Morgan Stanley
Morgan Stanley
$120$110
Sell
15.64%
Upside
Reiterated
02/26/25
Morgan Stanley Reaffirms Their Sell Rating on Glaukos (GKOS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glaukos

1 Month
xxx
Success Rate
10/11 ratings generated profit
91%
Average Return
+6.58%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 90.91% of your transactions generating a profit, with an average return of +6.58% per trade.
3 Months
xxx
Success Rate
9/11 ratings generated profit
82%
Average Return
+4.67%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +4.67% per trade.
1 Year
Success Rate
12/17 ratings generated profit
71%
Average Return
+36.90%
reiterated a buy rating 29 days ago
Copying David Saxon's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +36.90% per trade.
2 Years
xxx
Success Rate
12/17 ratings generated profit
71%
Average Return
+45.61%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +45.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GKOS Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
6
10
10
8
5
Buy
12
8
11
19
15
Hold
5
10
11
14
12
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
28
32
41
32
In the current month, GKOS has received 20 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. GKOS average Analyst price target in the past 3 months is 124.75.
Each month's total comprises the sum of three months' worth of ratings.

GKOS Financial Forecast

GKOS Earnings Forecast

Next quarter’s earnings estimate for GKOS is -$0.26 with a range of -$0.31 to -$0.20. The previous quarter’s EPS was -$0.24. GKOS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.47% of the time in the same period. In the last calendar year GKOS has Outperformed its overall industry.
Next quarter’s earnings estimate for GKOS is -$0.26 with a range of -$0.31 to -$0.20. The previous quarter’s EPS was -$0.24. GKOS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.47% of the time in the same period. In the last calendar year GKOS has Outperformed its overall industry.

GKOS Sales Forecast

Next quarter’s sales forecast for GKOS is $122.50M with a range of $121.10M to $124.76M. The previous quarter’s sales results were $124.12M. GKOS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 33.58% of the time in the same period. In the last calendar year GKOS has Outperformed its overall industry.
Next quarter’s sales forecast for GKOS is $122.50M with a range of $121.10M to $124.76M. The previous quarter’s sales results were $124.12M. GKOS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 33.58% of the time in the same period. In the last calendar year GKOS has Outperformed its overall industry.

GKOS Stock Forecast FAQ

What is GKOS’s average 12-month price target, according to analysts?
Based on analyst ratings, Glaukos’s 12-month average price target is 124.75.
    What is GKOS’s upside potential, based on the analysts’ average price target?
    Glaukos has 31.15% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GKOS a Buy, Sell or Hold?
          Glaukos has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Glaukos’s price target?
            The average price target for Glaukos is 124.75. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $165.00 ,the lowest forecast is $92.00. The average price target represents 31.15% Increase from the current price of $95.12.
              What do analysts say about Glaukos?
              Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of GKOS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis